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Hypertension after kidney transplant is a frequent occurrence in pediatric patients. It 
is a risk factor for graft loss and contributes to the significant burden of cardiovascular 
disease (CVD) in this population. The etiology of posttransplant hypertension is multifac-
torial including donor factors, recipient factors, medications, and lifestyle factors similar 
to those prevalent in the general population. Ambulatory blood pressure monitoring has 
emerged as the most reliable method for measuring hypertension in pediatric transplant 
recipients, and many consider it to be essential in the care of these patients. Recent 
technological advances including measurement of carotid intima-media thickness, pulse 
wave velocity, and myocardial strain using specked echocardiography and cardiac 
magnetic resonance imaging have improved our ability to assess CVD burden. Since 
hypertension remains underrecognized and inadequately treated, an early diagnosis and 
an appropriate control should be the focus of therapy to help improve patient and graft 
survival.
Keywords: kidney transplant, hypertension, pediatric, ambulatory blood pressure monitoring, carotid intima–
media thickness, pulse wave velocity, antihypertensive drugs
iNTRODUCTiON
Hypertension after renal transplantation is a common phenomenon with an estimated prevalence 
of 70–90% in adults and 58–89% in children (1–3). Long-standing hypertension has been associ-
ated with allograft dysfunction, premature atherosclerosis, and cardiomyopathy (4, 5).
Cardiovascular disease (CVD) is much more common among children with chronic kidney 
disease (CKD) and end-stage renal disease (ESRD) compared to the general population. CVD 
accounts for a large proportion of morbidity and mortality in this population (6). Renal transplan-
tation improves CVD risk. Compared to patients awaiting transplantation, transplant recipients 
experience a substantial reduction in the CVD-associated death rate, especially from adolescence 
onward while they maintain good graft function (7–11). However, hypertension remains a signifi-
cant and modifiable risk factor for CVD in pediatric transplant recipients. Studies have shown that 
transplant patients have better systolic and diastolic function than those receiving hemodialysis or 
peritoneal dialysis (PD), despite having increased prevalence of hypertension and left ventricular 
hypertrophy (LVH) (12). In addition to offering transplantation to ameliorate the cardiovascular 
effects of ESRD, aggressively treating blood pressure in transplant recipients would further reduce 
the prevalence of CVD.
The etiology of posttransplant hypertension is multifactorial encompassing donor-associated 
factors, side effects of immunosuppressive medications, underlying recipient disease, and possibly 
genetic factors, as seen in Figure 1. The treatment strategies vary by timing after transplant as well 
as the pathophysiological contributors to hypertension. This review will cover etiology of posttrans-
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eTiOLOGY OF HYPeRTeNSiON
Donor Factors
It has been well established that several independent donor 
risk factors predispose the transplant recipient to hypertension 
including deceased donor, older age, and donor hypertension 
(13, 14). It is theorized that the increased risk comes from longer 
cold ischemia time, damaged graft vessels from hypertension, 
and age-related glomerular dropout in older donors. Due to these 
reasons, most transplant centers do not accept donors beyond 
a certain age or those with hypertension for pediatric recipients 
except in extenuating circumstances. Extended criteria donor 
kidneys have been associated with increased risk of death from 
CVD in the adult population and usually are not accepted for 
pediatric recipients (15).
The kidney donor profile index (KDPI) scoring system, used 
to evaluate donor grafts, was recently introduced in the United 
States (16). Donors with lower KDPI have potential for better 
graft survival, and pediatric recipients get preference for donors 
with lower KDPI scores, and most pediatric transplant centers 
will not accept kidneys with high KDPI scores for children. 
There are no data yet on long-term CVD outcomes for transplant 
recipients based on donor KDPI scores.
Recently, donor genetic variants have been found to con-
tribute to poor graft function and posttransplant hypertension. 
Polymorphisms including apolipoprotein L1 (APOL1), ATP-
Binding Cassette Subfamily B Member 1 (ABCB1), Caveolin 1 
(CAV1), and ATP-Binding Cassette Subfamily C Member 2 
(ABCC2) have been shown to affect graft survival, hypertension, 
and calcineurin-induced nephrotoxicity (17–21). Currently, 
there is no standard for screening for these polymorphisms.
Recipient Factors
Recipient factors such as recurrence of original disease in the 
graft and presence of native kidneys are known contributors to 
posttransplant hypertension. Occasionally, native nephrectomies 
are performed prior to or at the time of transplant to help with 
management of hypertension (22). However, this is becoming an 
uncommon practice because recent data suggest that the benefit 
is limited (23).
Pediatric patients with pretransplant obesity have significantly 
higher systolic blood pressure (SBP) and worse glomerular fil-
tration rate (GFR) than children with normal body mass index 
prior to transplant (24). The incidence of pretransplant obesity is 
increasing mirroring the rise of obesity in the general pediatric 
population (25). As in the general population, the development 
of overweight or obesity after transplantation in children is 
associated with hypertension and poor glycemic control (26, 27). 
While these CVD risk factors can more pronounced due to the 
known side effects of immunosuppressant medications, the effect 
of obesity on hypertension in the pediatric transplant recipient 
has been shown to be independent of posttransplant use of 
steroids (28).
effects of Medications
Immunosuppressive medications play a significant role in the 
development of posttransplant hypertension. It has been well 
established that corticosteroids induce hypertension by increas-
ing renal salt and water reabsorption and increase in renal 
vascular resistance. Studies have shown that patients on steroid-
minimization protocols and patients undergoing late-withdrawal 
of steroids showed reduction in hypertension and obesity and 
improved lipid and carbohydrate metabolism (29).
The incidence of posttransplant hypertension significantly 
increased after calcineurin inhibitors (CNI) such as cyclosporine 
and tacrolimus became commercially available for use. A recent 
Greek cohort of pediatric transplant patients showed that there 
was an increased risk of hypertension for patients on a CNI-based 
immunosuppression protocol (14).
The mechanism of CNI-induced hypertension is primarily 
mediated by glomerular afferent arteriolar constriction leading 
to increased salt and water retention, in part through upregula-
tion of the thiazide-sensitive Na+-Cl− cotransporter (30, 31). 
Additional mechanisms include activation of renin angiotensin 
aldosterone system and secretion of reactive oxygen species 
(32, 33). An imbalance between vasoconstrictive molecules 
(endothelin, thromboxane, and prostaglandins) and vasodilatory 
nitric oxide also contributes to the development of hyperten-
sion (34, 35). Finally, prolonged CNI exposure causes increased 
production of transforming growth factor-β production, which 
leads to fibrosis and long-term graft damage (36–38). Tacrolimus 
has become the preferred CNI in clinical practice as it causes 
less hypertension and hyperlipidemia, as well as improved graft 
survival when compared to cyclosporine (39, 40).
Previously, it has been shown that mammalian target of rapa-
mycin (mTOR) inhibitors act synergistically with CNI to worsen 
hypertention (41). Brunkhorst et  al. (2015) recently compared 
the efficacy and safety of an everolimus and low-dose CSA regi-
men to standard dose cyclosporine and mycophenolate mofetil 
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therapy in 105 pediatric transplant patients. They found that the 
everolimus group had comparable graft function and survival 
but more dyslipidemia and arterial hypertension than the control 
group (42). This suggests that mTOR inhibitors have an effect on 
posttransplant hypertension independent of or in synergy with 
the CNI effect, although the precise mechanism is not yet known.
Transplant Renal Artery Stenosis (TRAS)
Transplant renal artery stenosis is the most common vascu-
lar complication after renal transplant, usually presenting 
2 months–2 years after transplant (43). Clinical signs are usually 
worsening or refractory hypertension with or without graft dys-
function (44). It has a reported prevalence of 1–23% and accounts 
for 1–5% of posttransplant hypertension (45).
Risk factors for TRAS include surgical technique, deceased 
donor, cytomegalovirus infection, and prolonged ischemia time 
(46). A recent study investigated the role of genetic polymor-
phisms in the myosin heavy chain 9 (MYH9) gene on TRAS. The 
product of this gene is heavily expressed in glomeruli, tubular, 
and renal capillaries as well as arteriolar endothelial cells. Donor 
organs found to carry the rs3752462 CC variant had a 10.9-fold 
increase in TRAS compared to the recipients carrying rs5756168 
TT variant that had a 3.45-fold decrease in risk (47).
Graft Dysfunction
Recurrent and De Novo Glomerular Diseases
Many underlying glomerular diseases in the recipient can recur 
in the transplant allograft including focal segmental glomerulo-
sclerosis (FSGS), atypical hemolytic uremic syndrome (aHUS), 
antiglomerular basement membrane disease, systemic lupus 
erythematosus nephritis, membranous glomerulonephritis 
(MGN), and membranoproliferative glomerulonephritis. Of 
these, the most common are aHUS and FSGS, the latter with a 
30–50% recurrence risk in the first transplant and 80–100% in 
subsequent transplants (48). Some transplant patients develop de 
novo glomerular disorders after transplant that may include FSGS 
and MGN. These glomerular disorders have the potential to cause 
hypertension, and poor blood pressure control will accelerate 
renal function decline (49–51).
Acute Rejection (AR)
Acute rejection can be T-cell and antibody mediated and is 
often associated with hypertension. Any transplant patient with 
sudden onset or worsening of hypertension should be assessed 
for AR. The hypertension in this case usually responds well to 
treatment of AR.
Chronic Rejection, Also Known As Chronic 
Transplant Glomerulopathy (TG)
Transplant glomerulopathy causes hypertension through pro-
gressive scarring and fibrosis. Recent data showed that non-HLA 
autoantibodies targeting the angiotensin II type-1 receptor have 
been linked to hypertension, and treatment with an angiotensin 
receptor blocker may be beneficial (52–54).
Common Risk Factors Prevalent in  
the General Population
While patients with ESRD have numerous additional risk 
factors compared to normal children for developing hyper-
tension, common risk factors for hypertension present in the 
general population also prevail in kidney transplant recipients. 
These risk factors include tobacco smoking, illicit drug use, 
medications for attention deficit hyperactivity disorder, 
high-salt diet, physical inactivity, obesity, sleep disturbances 
including obstructive sleep apnea, and genetic determinants of 
hypertension (55–59). Figure 2 outlines the common etiologies 
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observed for post-transplant hypertension in relation to time 
after transplant.
eFFeCT OF HYPeRTeNSiON ON CvD  
AND ALLOGRAFT FUNCTiON
Definitive cardiovascular outcomes such as stroke, myocardial 
infarction, and death are uncommon in the pediatric age 
group. Pediatric studies have relied on the use of intermediate 
endpoints such as LVH as measured by left ventricular mass 
index (LVMI), carotid intima-media thickness (cIMT), and 
pulse wave velocity (PWV) for CVD risk stratification. It has 
been well described that pediatric patients with CKD and 
ESRD have significantly increased cardiovascular morbidity 
and mortality compared to their healthy peers (60, 61). CVD 
accounts for approximately 30% of mortality among pediatric 
kidney transplant recipients (9).
Long-standing hypertension has been shown to result in LVH 
and increased LVMI and cIMT, all known risk factors for CVD 
(2). LVH is prevalent in approximately 50% of patients with CKD 
and ESRD and in kidney transplant recipients. A single-center 
study comparing pretransplant echocardiography (ECHO) with 
posttransplant ECHO showed that interval decrease in indexed 
SBP was the only predictor of LVMI improvement on multivariate 
analysis (62). A cross-sectional study in 2004 found that children 
with a kidney transplant were more likely to have elevated LVMI 
and diastolic dysfunction than healthy controls (63). However, 
another study found no difference in systolic or diastolic func-
tion between normotensive and hypertensive pediatric transplant 
recipients using the same tissue Doppler technique (2).
Evidence suggests that hypertension itself, regardless of BP 
level, is associated with LVH. Specifically, Hamdani et al. showed 
that treated hypertensive individuals with a normal blood pressure 
had a greater prevalence of LVH than normotensive individuals 
not treated with antihypertensive medications. In this same study, 
a large pediatric cohort of 221 patients evaluated with ambulatory 
blood pressure monitoring (ABPM), it was noted that patients 
with normal blood pressure who did not require antihypertensive 
medications had less allograft dysfunction than patients taking 
antihypertensive medications and even in those whose BP was 
in normal range (64). This emphasizes the point that children 
with pharmacologically controlled hypertension are still at an 
increased CVD risk compared to normotensive individuals 
and require close screening for intermediate risk factors and 
endpoints.
Masked hypertension as determined by ABPM in both 
patients receiving and not receiving antihypertensive therapy 
has an estimated prevalence of 25–35% (65). While smaller stud-
ies have not been able to find an association between masked 
hypertension and graft function, a recent study by Hamdani 
et  al. showed that pediatric transplant recipients with masked 
hypertension had significantly worse graft function than their 
normotensive peers (66).
A study aimed at assessing CVD risk factors in pediatric 
transplant patients found that there was a negative correlation 
between GFR and SBP  ±  diastolic blood pressure (DBP) on 
univariate analysis. There was a noted trend of worsening hyper-
tension with increasingly poor graft function on multivariate 
analysis, but the study was underpowered to detect this effect 
(67). A Finnish cohort found that only decreased diastolic dip-
ping could predict lower GFR (68). More recently in a Greek 
cohort, 20-year graft survival was superior for patients without 
hypertension at 10 years follow-up after kidney transplant com-
pared to those with hypertension (100 vs. 44.4%, P < 0.05) (14). 
As well established in native kidneys with CKD, the presence of 
poorly controlled hypertension also negatively affects renal graft 
function over time.
A Dutch cohort study looking at long-term CVD outcomes 
in kidney transplant recipients (with an average follow-up of 
15. 5  years) who developed ESRD as children (0–14  years of 
age) found that ~50% of males and 40% of females had LVH, 
13% had diastolic dysfunction, and aortic valve calcification 
was seen in 25% males and 12% female patients (69). Duration 
of PD was independently associated with development of aortic 
valve calcifications and diastolic dysfunction increased over time 
and correlated with low GFR. This study also demonstrated an 
era effect as patients who developed ESRD in the 1970s and 
1980s had increased prevalence of CVD prior to more aggres-
sive blood pressure control, ubiquitous use of erythropoietin-
stimulating agents, frequent avoidance of aluminum, and 
limited use of calcium-based phosphorus binders (69). A similar 
recent Dutch cohort still continued to show era effects in CVD 
outcomes with improved management of hypertension and 
hyperlipidemia (70).
In conclusion, children with CKD/ESRD come to transplant 
with significant burden of hypertension and CVD. With trans-
plantation, their CVD risk improves overall but may be negatively 
impacted by poor control of blood pressure, by decline in GFR 
overtime, and by the presence of hyperlipidemia, obesity, and 
hyperglycemia.
BLOOD PReSSURe MeASUReMeNT AND 
ASSeSSMeNT OF CvD RiSK
Screening for hypertension can be achieved by several methods 
that include casual clinic blood pressure measurement, home and 
school blood pressure measurement, and 24-h ABPM. ABPM 
has been shown to be the most reliable method for measuring 
blood pressure. It also has the added benefit of determining BP 
load and predicting LVH (71–73). Pediatric patients with ESRD 
who lack nocturnal dipping as characterized by a decrease of 
>10% in nighttime blood pressure compared to daytime blood 
pressure are deemed to be at an increased risk of LVH. However, 
this was not borne out in another recent study that showed that 
hypertensive children without ESRD who have nocturnal non-
dipping have similar prevalence of LVH compared to hyperten-
sive children without non-dipping (74, 75).
Before widespread use of ABPM, we must recognize its cur-
rent limitations. Primarily, controversy remains about how to 
best interpret ABPM results due to lack of diverse normative data. 
Currently available normative data are based on ABPM measure-
ments of 949 healthy children published by the German Working 
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Group of Pediatric Hypertension (76). All children included in 
this study were of European descent, relatively few short children 
(<140 cm) were included, and there was a lack of variability in 
DBPs within the group raising question about the algorithm used 
to calculate the normal values.
Carotid intimal Media Thickness
High-resolution ultrasonography provides a non-invasive 
method for measuring cIMT. Increased cIMT, a marker for the 
development and progression of vascular calcification, has been 
documented in children as young as 8 years and correlates with 
duration of CKD, time on dialysis, hyperhomocysteinemia, and 
increased calcium–phosphorus product (77, 78). A recent meta-
analysis showed that pediatric solid organ transplant recipients 
have increased cIMT compared to healthy controls (79). Increased 
cIMT has been shown to be a strong risk factor for myocardial 
infarction and stroke in adults (80). Childhood hypertension has 
been shown to predict increased adult cIMT by the Childhood 
Cardiovascular Cohort (i3C) (81).
Hypertension has been shown to have a linear correlation with 
cIMT in adults (82). Balzano et al. showed that although renal 
transplant recipients had increased cIMT and LVMI compared 
to healthy controls, there was no progression or worsening in 
those who underwent annual ABPM monitoring and had well-
controlled hypertension (83). This study is reassuring of the fact 
that while renal transplant recipients have greater cIMT and 
LVH than healthy controls, regular blood pressure monitoring 
and aggressive blood pressure control can halt the progression of 
these intermediate CVD outcomes.
Pulse wave velocity
Arterial PWV is a sensitive marker of arterial stiffness, which 
makes it a good surrogate endpoint for CVD (84). Increased 
arterial stiffness is an independent predictor of survival in the 
general population and in CKD patients (85). Normative pediat-
ric reference values are available based on a study of 1,000 healthy 
children, which enabled the calculation of age- and height-
specific SD scores (86). This study was performed on patients 
in Hungary, Italy, and Algeria with ages ranging between 6 and 
20 years. Multiple regression analysis showed that age, height, and 
blood pressure were major predictors of PWV.
Chronic kidney disease patients have been shown to have 
increased PWV. The recent 4C Study looked at numerous cardio-
vascular endpoints including PWV and found that 20.1% of CKD 
patients in their cohort had elevated PWV. In their analysis, the 
rise in PWV was independent of eGFR and moderately correlated 
with cIMT (87). Sinha et al. (2015) showed that in children with 
advanced CKD, only poorly controlled hypertension but not GFR 
was associated with a change in arterial stiffness when compared 
to healthy matched controls (88). In addition, the Young Finn 
study showed that childhood hypertension was related to higher 
adult PWV (89). In pediatric kidney transplant recipients, PWV 
has been shown to be increased compared to control patients 
matched for age and weight/height (26, 90). Since pediatric 
kidney transplant recipients have ongoing CKD, strict BP control 
may help to lower PWV and future cardiovascular risk in this 
population.
Myocardial Strain Analysis
The majority of coronary artery disease in CKD patients is 
asymptomatic and may initially present with arrhythmia and 
sudden death. Assessing the degree of myocardial strain using 
ECHO or magnetic resonance (MR) imaging can detect more 
subtle changes of impaired cardiovascular function, thus offering 
an opportunity for early intervention.
Echocardiographic strain imaging helps to objectively quan-
tify myocardial function (91). An extension of this is global 
longitudinal strain (GLS) analysis, which can be used to detect 
subtle changes in left ventricular function. GLS has been shown 
to be independently associated with all-cause and CV mortality 
in adult patients with CKD and after renal transplant. It is a 
more reliable marker than ejection fraction for mortality (92, 
93). Pirat et al. demonstrated that ESRD patients with a normal 
ejection fraction had signs of subclinical myocardial disease 
as determined by impaired longitudinal, circumferential, and 
radial strain as well as strain rate (94). In that same study, 
patients who underwent renal transplantation had improve-
ment in all of these parameters compared to the patients receiv-
ing chronic dialysis. The clinical characteristics that negatively 
affect GLS and basal longitudinal systolic strain were shown to 
include increased interventricular septal thickness, diabetes, 
low ejection fraction, increased DBP, and regular dialysis (95). 
This again highlights the role of hypertension as a modifiable 
risk factor.
Cardiac MR is a relatively newer imaging modality that can 
provide additional information about CV risks in the CKD 
population. Blood oxygen level-dependent cardiac MR can be 
used to assess myocardial tissue oxygenation. A recent study 
employing this technique found that patients with CKD and renal 
transplant without known coronary artery disease had impaired 
myocardial response to stress, independent of the presence of 
diabetes mellitus, LVH, and myocardial scar (96). An additional 
use for cardiac MR imaging is to estimate LVM, which has been 
shown to closely correlate with autopsy findings of heart size. 
A recent study compared ECHO and cardiac MR in their ability 
to measure LVM in hypertensive pediatric patients and found 
that ECHO generally overestimated the presence of LVM and 
cardiac MR was a much more reliable method (97).
As these technologies become more readily available and cost-
effective in clinical practice, they will be able to offer more reliable 




There are no published guidelines or recommendations for the 
immediate postoperative management of kidney transplant 
recipients. We will describe our center’s practice based on our 
clinical experience in this section. In the immediate postoperative 
period (first week), the most likely etiology of hypertension is 
fluid overload, side effect of high-dose steroid therapy for induc-
tion, and native kidney disease. In the first few postoperative 
days, permissive hypertension is tolerated to ensure adequate 
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graft perfusion especially in small children. Size discrepancy 
of the donor and recipient arteries and relatively lower blood 
pressure in the child can compromise early graft perfusion and 
predisposition to thrombus formation. This necessitates higher 
patient blood pressures and may require vasopressor support to 
achieve this.
After a few days postoperatively, excess fluid begins to 
mobilize and move into the intravascular space, contributing to 
hypertension. Allowing gradual diuresis back to the patient’s dry 
weight will often result in decrease of the systemic blood pressure. 
However, patients frequently need to be restarted or initiated on 
antihypertensive medications during the postoperative period.
Long-term Management
A holistic approach to the long-term management of hyperten-
sion should be pursued in the pediatric transplant recipient. As 
the goal of hypertensive management is ultimately to prolong 
patient and graft survival and decrease CVD, this approach 
should include close monitoring and management of graft 
function as well as adherence to medications, diet, and exercise. 
Many review papers have been published on the pharmacologic 
management of hypertension (1, 98, 99). The current KDIGO 
position is that no class of antihypertensive medications is 
contraindicated in transplant recipients (100). In clinical prac-
tice, calcium channel blockers (CCBs) and ACE-I are the most 
common first-line medications (101–103). While permissive 
hypertension is tolerated immediately after transplant surgery, 
the ultimate goal of therapy should be to target normal blood 
pressures (<90th percentile) and try to achieve control near the 
50th percentile for age.
As with hypertension in patients without renal transplant, 
pharmacologic therapy should be aimed at addressing the 
underlying etiology. In patients on CNI-based immunosup-
pression, afferent arteriole vasoconstriction contributes to 
hypertension, and therefore, a use of CCBs is usually the 
first-line therapy due to its vasodilatory properties. CCBs 
have a very good safety profile and have been shown to be 
efficacious in this patient population for both blood pressure 
control and improvement of GFR compared to placebo treated 
patients (101). In non-transplant patients, the benefit of ACE-I 
in the pediatric CKD population with proteinuria has been 
well described (51). Less concrete evidence exists for the use of 
ACE-I in kidney transplant recipients. Knoll et al. performed a 
multicenter double-blind placebo-controlled study comparing 
ramipril to placebo and found no benefit in allograft survival 
in the treatment group. His study was underpowered to detect 
a difference and may account for their null results (104). A 
recent meta-analysis to look at the effects of ACE-I on graft 
survival also found no benefit (105). A small case series in a 
pediatric population found that ACE-I appeared to stabilize 
creatinine in patients with chronic allograft dysfunction, but 
statistical analysis could not support the renoprotective effect 
of ACE-I on long-term graft survival (106). Meta-analysis 
by Cross et  al. showed that therapy with ACE-I can reduce 
proteinuria, however there are not enough data to support 
that this improves graft survival (101). Diuretics are not usu-
ally employed in the pediatric transplant population due to 
the need to maintain adequate hydration; however, a thiazide 
diuretic may be effective in helping control CNI-mediated 
hypertension due to its action through the thiazide-sensitive 
Na-Cl channel (30, 107).
Dietary Counseling
While pharmacological interventions have an important role in 
the management of hypertension, dietary and exercise counseling 
need to be at the forefront of long-term management of transplant 
recipients.
Diets high in sodium and low in potassium have been shown 
to aggravate hypertension. In a Belgian study of adult patients, 
dietary history and urinary sodium and potassium excretion 
were evaluated. While sodium intake did not differ between the 
two groups (~10 g/day), patients with controlled blood pressure 
consumed higher amounts of potassium by regularly eating 
more fruits and vegetables, which lowered their observed Na+/
K+ ratio (108). Asai et  al. demonstrated that repeated dietary 
counseling resulted in a statistically significant reduction in mean 
24-h urinary sodium excretion and SBP (109). Similarly, de Vries 
et al. also showed that dietary sodium restriction in adult kidney 
transplant recipients resulted in statistically significant reductions 
in SBP and DBP (110). Both of these studies had small sample 
size, and therefore, it is impressive that the noted changes in blood 
pressure were able to reach statistical significance.
In accordance with these findings, published nutritional 
guidelines for renal transplant recipients include low-sodium 
diet and weight loss in obese individuals to optimize blood pres-
sure management (111). Counseling of patients should be done 
routinely, as infrequent counseling has been shown to be not 
effective (112).
Systems-Based Approach
Changes and improvement in management of hypertension in 
the pediatric kidney transplant population can be approached 
using quality improvement methodology. Because this is a 
complex multifaceted problem that affects patients’ long-term 
outcomes and requires multidisciplinary cooperation, this can 
be addressed by employing the Chronic Care Model as suggested 
by Hooper and Mitsnefes (113). Recommendations include 
implementation of clinic visit checklists to ensure that blood 
pressure, diet, and lifestyle risk factors are addressed regularly 
at every clinic visit, augmenting the electronic health record 
(EHR) to calculate blood pressure percentiles, pop-up remind-
ers for annual ABPM screening, and employing novel technol-
ogy to encourage activity and participation among transplant 
recipients.
CONCLUSiON
Hypertension in the pediatric kidney transplant recipients is 
highly prevalent and often underrecognized and undertreated. 
This contributes to worse allograft function and long-term risk of 
CVD in early adulthood and partly accounts for the significantly 
increased mortality in this patient population. Hypertension is a 
modifiable risk factor that should be aggressively monitored and 
treated, as summarized in Figure  3. Annual 24-h ABPM and 
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Controlled hypertension helps
to preserve allograft function
and decrease cardiovascular
morbidity and mortality     
FiGURe 3 | Key points.
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echocardiography are useful tools to asses CVD risk and monitor 
blood pressure control. Newer technologies such as measure-
ment of cIMT, PWV, and myocardial strain can be considered 
to enhance CVD risk stratification. Treatment should include 
a combination of pharmacological and lifestyle interventions 
to optimize care utilizing a multidisciplinary team. Currently, 
quality improvement methodology and EHR technology provide 
an opportunity to customize workflows and build in templates/
reminders to optimize patient care and improve patient outcomes.
FUTURe ReSeARCH
There are many gaps in our knowledge in this field that would 
benefit from further research including but not limited to CVD 
outcomes based on the donor KDPI; genetic polymorphism of 
donors affecting posttransplant hypertension in transplant recipi-
ents; ABPM normative data of diverse ethnic populations; blood 
pressure percentile treatment goals for transplant recipients; 
effect of ACE-I on long-term graft survival, and finally, address-
ing barriers to adherence at both provider and patient level with 
adequate treatment plan.
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